[
  {
    "ts": "2025-06-18T15:08:00+00:00",
    "headline": "21GRAMS Wins Its First Gold Lion for Branded Pharma Campaign at Cannes Lions International Festival of Creativity",
    "summary": "CANNES, France & NEW YORK, June 18, 2025--21GRAMS Named No. 2 Healthcare Agency and Real Chemistry Ranked No. 2 Healthcare Network at Cannes Lions International Festival of Creativity",
    "url": "https://finance.yahoo.com/news/21grams-wins-first-gold-lion-150800251.html",
    "source": "Business Wire",
    "provider": "yfinance",
    "raw": {
      "id": "009973c5-1f26-3b55-b132-a831bbb5e6f0",
      "content": {
        "id": "009973c5-1f26-3b55-b132-a831bbb5e6f0",
        "contentType": "STORY",
        "title": "21GRAMS Wins Its First Gold Lion for Branded Pharma Campaign at Cannes Lions International Festival of Creativity",
        "description": "",
        "summary": "CANNES, France & NEW YORK, June 18, 2025--21GRAMS Named No. 2 Healthcare Agency and Real Chemistry Ranked No. 2 Healthcare Network at Cannes Lions International Festival of Creativity",
        "pubDate": "2025-06-18T15:08:00Z",
        "displayTime": "2025-06-18T15:08:00Z",
        "isHosted": true,
        "bypassModal": false,
        "previewUrl": null,
        "thumbnail": {
          "originalUrl": "https://media.zenfs.com/en/business-wire.com/6ff6be7e72eb73a0c989415ed31caba7",
          "originalWidth": 480,
          "originalHeight": 270,
          "caption": "21GRAMS and Biogen take home the Gold Pharma Lion trophy for Friedreich's Back campaign.",
          "resolutions": [
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/uTyj_mjFPN5dsFM0P560XQ--~B/aD0yNzA7dz00ODA7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/business-wire.com/6ff6be7e72eb73a0c989415ed31caba7.cf.webp",
              "width": 480,
              "height": 270,
              "tag": "original"
            },
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/yGpF72x7i27gDSxv2SsLkA--~B/Zmk9c3RyaW07aD0xMjg7dz0xNzA7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/business-wire.com/6ff6be7e72eb73a0c989415ed31caba7.cf.webp",
              "width": 170,
              "height": 128,
              "tag": "170x128"
            }
          ]
        },
        "provider": {
          "displayName": "Business Wire",
          "url": "http://www.businesswire.com/"
        },
        "canonicalUrl": {
          "url": "https://finance.yahoo.com/news/21grams-wins-first-gold-lion-150800251.html",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "clickThroughUrl": {
          "url": "https://finance.yahoo.com/news/21grams-wins-first-gold-lion-150800251.html",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "metadata": {
          "editorsPick": false
        },
        "finance": {
          "stockTickers": [
            {
              "symbol": "BIIB"
            }
          ],
          "premiumFinance": {
            "isPremiumNews": false,
            "isPremiumFreeNews": false
          }
        },
        "storyline": null
      }
    }
  },
  {
    "ts": "2025-06-18T13:45:13+00:00",
    "headline": "H.C. Wainwright sees potential competition for Sage from Biogen",
    "summary": "H.C. Wainwright analyst Douglas Tsao says that while a takeover of Sage Therapeutics (SAGE) comes as no surprise, but a deal with Supernus (SUPN) is unexpected, and “leaves open the door for additional competition.” The merger agreement includes a “modest” breakup fee of just $22.4M payable to Supernus in the event Sage accepts a superior offer, the analyst tells investors in a research note. The firm believes the “relatively modest breakup fee” would not dissuade Biogen (BIIB) from pursuing a b",
    "url": "https://finance.yahoo.com/news/h-c-wainwright-sees-potential-134513677.html",
    "source": "TipRanks",
    "provider": "yfinance",
    "raw": {
      "id": "73eff002-85c7-34ff-b346-a6817c61fe0f",
      "content": {
        "id": "73eff002-85c7-34ff-b346-a6817c61fe0f",
        "contentType": "STORY",
        "title": "H.C. Wainwright sees potential competition for Sage from Biogen",
        "description": "",
        "summary": "H.C. Wainwright analyst Douglas Tsao says that while a takeover of Sage Therapeutics (SAGE) comes as no surprise, but a deal with Supernus (SUPN) is unexpected, and “leaves open the door for additional competition.” The merger agreement includes a “modest” breakup fee of just $22.4M payable to Supernus in the event Sage accepts a superior offer, the analyst tells investors in a research note. The firm believes the “relatively modest breakup fee” would not dissuade Biogen (BIIB) from pursuing a b",
        "pubDate": "2025-06-18T13:45:13Z",
        "displayTime": "2025-06-18T13:45:13Z",
        "isHosted": true,
        "bypassModal": false,
        "previewUrl": null,
        "thumbnail": {
          "originalUrl": "https://media.zenfs.com/en/tipranks_452/87b9ff78d08b9d461f46ab67f57ff730",
          "originalWidth": 192,
          "originalHeight": 192,
          "caption": "https://www.tipranks.com/news/the-fly/h-c-wainwright-sees-potential-competition-for-sage-from-biogen-thefly",
          "resolutions": [
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/L9IzJML6_bSSnd9izcZMPg--~B/aD0xOTI7dz0xOTI7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/tipranks_452/87b9ff78d08b9d461f46ab67f57ff730.cf.webp",
              "width": 192,
              "height": 192,
              "tag": "original"
            },
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/sFvQedlyM82OPhSmm4ES5A--~B/Zmk9c3RyaW07aD0xMjg7dz0xNzA7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/tipranks_452/87b9ff78d08b9d461f46ab67f57ff730.cf.webp",
              "width": 170,
              "height": 128,
              "tag": "170x128"
            }
          ]
        },
        "provider": {
          "displayName": "TipRanks",
          "url": "https://www.tipranks.com/"
        },
        "canonicalUrl": {
          "url": "https://finance.yahoo.com/news/h-c-wainwright-sees-potential-134513677.html",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "clickThroughUrl": {
          "url": "https://finance.yahoo.com/news/h-c-wainwright-sees-potential-134513677.html",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "metadata": {
          "editorsPick": false
        },
        "finance": {
          "stockTickers": [
            {
              "symbol": "BIIB"
            },
            {
              "symbol": "SUPN"
            },
            {
              "symbol": "SAGE"
            }
          ],
          "premiumFinance": {
            "isPremiumNews": false,
            "isPremiumFreeNews": false
          }
        },
        "storyline": null
      }
    }
  },
  {
    "ts": "2025-06-18T11:30:00+00:00",
    "headline": "Biogen Initiates Phase 3 Pediatric Study of Omaveloxolone for the Treatment of Friedreich Ataxia",
    "summary": "Global Phase 3 BRAVE study will evaluate the efficacy and safety of omaveloxolone in children 2 to <16 years old with Friedreich ataxia, a rare neurodegenerative disorderBRAVE study will explore the potential of omaveloxolone to address the critical unmet need of the pediatric FA populationOmaveloxolone is currently marketed under the brand name SKYCLARYS® for the treatment of adults and adolescents aged 16 years and older affected by Friedreich ataxia CAMBRIDGE, Mass., June 18, 2025 (GLOBE NEWS",
    "url": "https://finance.yahoo.com/news/biogen-initiates-phase-3-pediatric-113000810.html",
    "source": "GlobeNewswire",
    "provider": "yfinance",
    "raw": {
      "id": "9b49235c-c0a9-3843-895b-178f77db1bbf",
      "content": {
        "id": "9b49235c-c0a9-3843-895b-178f77db1bbf",
        "contentType": "STORY",
        "title": "Biogen Initiates Phase 3 Pediatric Study of Omaveloxolone for the Treatment of Friedreich Ataxia",
        "description": "",
        "summary": "Global Phase 3 BRAVE study will evaluate the efficacy and safety of omaveloxolone in children 2 to <16 years old with Friedreich ataxia, a rare neurodegenerative disorderBRAVE study will explore the potential of omaveloxolone to address the critical unmet need of the pediatric FA populationOmaveloxolone is currently marketed under the brand name SKYCLARYS® for the treatment of adults and adolescents aged 16 years and older affected by Friedreich ataxia CAMBRIDGE, Mass., June 18, 2025 (GLOBE NEWS",
        "pubDate": "2025-06-18T11:30:00Z",
        "displayTime": "2025-06-18T11:30:00Z",
        "isHosted": true,
        "bypassModal": false,
        "previewUrl": null,
        "thumbnail": {
          "originalUrl": "https://media.zenfs.com/en/globenewswire.com/d8db71a830aa632e702f24ebd736c00d",
          "originalWidth": 865,
          "originalHeight": 290,
          "caption": "",
          "resolutions": [
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/IDD9DHtEaM8wc.4J0e2kkA--~B/aD0yOTA7dz04NjU7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/globenewswire.com/d8db71a830aa632e702f24ebd736c00d.cf.webp",
              "width": 865,
              "height": 290,
              "tag": "original"
            },
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/iODOrgJZ_MV95T9B.jt0vw--~B/Zmk9c3RyaW07aD0xMjg7dz0xNzA7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/globenewswire.com/d8db71a830aa632e702f24ebd736c00d.cf.webp",
              "width": 170,
              "height": 128,
              "tag": "170x128"
            }
          ]
        },
        "provider": {
          "displayName": "GlobeNewswire",
          "url": "https://www.globenewswire.com/"
        },
        "canonicalUrl": {
          "url": "https://finance.yahoo.com/news/biogen-initiates-phase-3-pediatric-113000810.html",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "clickThroughUrl": {
          "url": "https://finance.yahoo.com/news/biogen-initiates-phase-3-pediatric-113000810.html",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "metadata": {
          "editorsPick": false
        },
        "finance": {
          "stockTickers": [
            {
              "symbol": "BIIB"
            }
          ],
          "premiumFinance": {
            "isPremiumNews": false,
            "isPremiumFreeNews": false
          }
        },
        "storyline": null
      }
    }
  }
]